Whitehawk Therapeutics (NASDAQ:WHWK – Get Free Report) and BeyondSpring (NASDAQ:BYSI – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, risk, dividends, analyst recommendations, institutional ownership and earnings.
Insider & Institutional Ownership
52.1% of Whitehawk Therapeutics shares are held by institutional investors. Comparatively, 40.3% of BeyondSpring shares are held by institutional investors. 49.9% of Whitehawk Therapeutics shares are held by insiders. Comparatively, 29.3% of BeyondSpring shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Volatility and Risk
Whitehawk Therapeutics has a beta of 0.92, suggesting that its stock price is 8% less volatile than the S&P 500. Comparatively, BeyondSpring has a beta of -0.21, suggesting that its stock price is 121% less volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of current ratings and target prices for Whitehawk Therapeutics and BeyondSpring, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Whitehawk Therapeutics | 1 | 0 | 7 | 0 | 2.75 |
| BeyondSpring | 1 | 0 | 0 | 0 | 1.00 |
Whitehawk Therapeutics presently has a consensus target price of $8.33, suggesting a potential upside of 156.41%. Given Whitehawk Therapeutics’ stronger consensus rating and higher probable upside, equities research analysts plainly believe Whitehawk Therapeutics is more favorable than BeyondSpring.
Profitability
This table compares Whitehawk Therapeutics and BeyondSpring’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Whitehawk Therapeutics | N/A | -53.89% | -49.97% |
| BeyondSpring | N/A | N/A | -28.88% |
Valuation & Earnings
This table compares Whitehawk Therapeutics and BeyondSpring”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Whitehawk Therapeutics | $7.14 million | 25.95 | -$20.60 million | ($1.12) | -2.90 |
| BeyondSpring | $1.75 million | 10.46 | -$1.01 million | ($0.12) | -3.71 |
BeyondSpring has lower revenue, but higher earnings than Whitehawk Therapeutics. BeyondSpring is trading at a lower price-to-earnings ratio than Whitehawk Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Whitehawk Therapeutics beats BeyondSpring on 8 of the 12 factors compared between the two stocks.
About Whitehawk Therapeutics
Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.
About BeyondSpring
BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type. In addition, the company develops Plinabulin in combination with various immuno-oncology agents and chemotherapy or radiation, including; nivolumab, a PD-1 antibody that is has completed phase 1 clinical trials for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers; and pembrolizumab, etoposide, and platinum to treat extensive-stage small cell lung cancer. Further, it engages in the development of three small molecule immune agents in preclinical stages; and a drug discovery platform to develop therapeutic agents from internal research and development efforts and from collaboration. The company was founded in 2010 and is headquartered in Florham Park, New Jersey.
Receive News & Ratings for Whitehawk Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Whitehawk Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
